Tempus AI vs Tilray Brands Inc — how do they compare? Tempus AI trades at $70.55 (market cap $12.77B), while Tilray Brands Inc trades at $3.64 (market cap $549.01M). The key difference: Tempus AI is far larger — about 23.3× Tilray Brands Inc's market cap, and Tempus AI is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tempus AI for 22 Days and Tilray Brands Inc for 31 Days on average.
| TEM | TLRY | |
|---|---|---|
Market Cap | $12.77B | $549.01M |
Volume | 8,980,490 | 3,292,073 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.28 | $21.00 |
52-Week Low | $41.55 | $3.57 |
Typical Hold Time | 22 Days | 31 Days |
Enterprise Value | $13.40B | $716.15M |
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Tilray Brands (TLRY) trades at $3.715, down 1.72% on the day, as the stock continues to face significant pressure with bearish technical signals and fundamental challenges. The company reported a substantial net loss of $2.19 billion in 2025 despite $821 million in revenue, with negative cash flow from operations of $94.6 million. Recent earnings have consistently missed expectations, and technical indicators show a bearish trend with the stock trading near key support levels.
While TLRY shows attractive valuation metrics with P/S of 0.45 and P/B of 0.34, the company faces substantial execution risks amid persistent losses and negative cash flow. Analyst sentiment remains cautious with only 25% buy ratings, though the consensus price target of $65.01 suggests significant upside potential if the company can achieve profitability and growth targets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →